Artwork

Indhold leveret af CommonSpirit Health Physician Enterprise. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af CommonSpirit Health Physician Enterprise eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

5-Minute Check In: Tumor-Infiltrating Lymphocyte Therapy in Advanced Melanoma

7:28
 
Del
 

Manage episode 393563284 series 3291352
Indhold leveret af CommonSpirit Health Physician Enterprise. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af CommonSpirit Health Physician Enterprise eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Guest: Dr. Christopher Huerter, Professor and Division Chief Dermatology at Creighton University School of Medicine
Breakthrough treatments: Checkpoint inhibitors like Ipilimumab have changed the way we treat melanoma. Now, a new cutting-edge adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has shown promise in metastatic melanoma treatment trials. A new phase III trial compares TIL to Ipilimumab immunotherapy as first- or second-line treatment in patients with advanced melanoma with remarkable results.
Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2210233

  continue reading

99 episoder

Artwork
iconDel
 
Manage episode 393563284 series 3291352
Indhold leveret af CommonSpirit Health Physician Enterprise. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af CommonSpirit Health Physician Enterprise eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Guest: Dr. Christopher Huerter, Professor and Division Chief Dermatology at Creighton University School of Medicine
Breakthrough treatments: Checkpoint inhibitors like Ipilimumab have changed the way we treat melanoma. Now, a new cutting-edge adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has shown promise in metastatic melanoma treatment trials. A new phase III trial compares TIL to Ipilimumab immunotherapy as first- or second-line treatment in patients with advanced melanoma with remarkable results.
Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2210233

  continue reading

99 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning